Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -24.06% is 53% above its 5-year average of -50.78%, near the high end of its 5-year range (-134.37%–-5.53%).
45.74% above its 12-month average of -44.34%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -1.32%.
RETURN ON ASSETS (ROA)
-24.06%
RETURN ON ASSETS (ROA) AVG TTM
-44.34%
RETURN ON ASSETS (ROA) AVG 3Y
-68.40%
RETURN ON ASSETS (ROA) AVG 5Y
-50.78%
RETURN ON ASSETS (ROA) AVG 10Y
-31.71%
RETURN ON ASSETS (ROA) AVG 15Y
-14.78%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.74%
CURRENT VS 3Y AVG
+64.82%
CURRENT VS 5Y AVG
+52.62%
CURRENT VS 10Y AVG
+24.12%
CURRENT VS 15Y AVG
-62.76%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.55%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-2.14%
vs the sector median at left
Canopy Growth Corporation
Market Cap
$373.40M
Return on Assets (ROA)
-24.06%
TTM Avg
-44.34%
3Y Avg
-68.40%
5Y Avg
-50.78%
Market Cap
$368.91M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$366.39M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$363.54M
Return on Assets (ROA)
53.28%
TTM Avg
-50.19%
3Y Avg
-57.97%
5Y Avg
-53.56%
Market Cap
$348.85M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$348.59M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$345.48M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
Market Cap
$406.47M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$339.15M
Return on Assets (ROA)
-70.63%
TTM Avg
-82.15%
3Y Avg
-59.06%
5Y Avg
-50.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canopy Growth Corporation (CGC) | $373.40M | -24.06% | -44.34% | -68.40% | -50.78% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -4.29% | -7.44% | -40.66% | -49.61% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -21.30% | -29.99% | -30.23% | -24.37% |
| Agenus Inc. (AGEN)vs › | $363.54M | 53.28% | -50.19% | -57.97% | -53.56% |
| Embecta Corp. (EMBC)vs › | $348.85M | 6.92% | 7.42% | 10.30% | 25.30% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -24.64% | -45.98% | -40.55% | -44.33% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -39.85% | -37.20% | -38.95% | -33.46% |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -23.05% | -30.00% | -27.77% | -27.77% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | -70.63% | -82.15% | -59.06% | -50.33% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | -41.33% | -54.52% | -54.52% | -54.52% |
ROA
-24.1%
ROE
-38.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -23.50% |
| 2025-03-31 | -65.18% |
| 2024-03-31 | -50.55% |
| 2023-03-31 | -134.37% |
| 2022-03-31 | -5.53% |
| 2021-03-31 | -25.57% |
| 2020-03-31 | -27.42% |
| 2019-03-31 | -8.43% |
| 2018-03-31 | -4.68% |
| 2017-03-31 | -1.11% |
| 2016-03-31 | -2.44% |
| 2014-12-31 | -18.70% |
| 2013-12-31 | -18.10% |
| 2013-07-31 | -12.72% |
| 2012-07-31 | -3.93% |
| 2011-07-31 | -4.27% |
| 2010-07-31 | -4.58% |
